Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
Pazopanib is an oral angiogenesis inhibitor targeting vascular growth factor receptor-1, -2, and -3, platelet derived growth factor receptor-α, platelet derived growth factor receptor-β, and KIT that has demonstrated activity against a variety of adult cancer xenografts. Pazopanib was tested against a panel of pediatric rhabdomyosarcoma and Ewing sarcoma xenografts at a dose of 108 mg/kg/day or 100 mg/kg twice daily, administered orally for 28 days. While no objective responses were observed, pazopanib induced statistically significant differences in event-free survival compared to controls in approximately one-half of the sarcoma xenograft models tested. Though well tolerated, pazopanib showed limited activity against the sarcoma models evaluated, with the best tumor responses being growth delay.
Duke Scholars
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Xenograft Model Antitumor Assays
- Vascular Endothelial Growth Factors
- Sulfonamides
- Sarcoma, Ewing
- Rhabdomyosarcoma
- Receptor, Platelet-Derived Growth Factor beta
- Pyrimidines
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Mice, SCID
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Xenograft Model Antitumor Assays
- Vascular Endothelial Growth Factors
- Sulfonamides
- Sarcoma, Ewing
- Rhabdomyosarcoma
- Receptor, Platelet-Derived Growth Factor beta
- Pyrimidines
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Mice, SCID